Comparison of $[^{18}\text{F}]$DOPA and $[^{68}\text{Ga}]$DOTA-TOC as a PET imaging tracer before peptide receptor radionuclide therapy

Emile B. Veenstra$^1$*, Adrienne H. Brouwers$^1$, Derk Jan A. de Groot$^2$, Johannes Hofland$^3$, Annemiek M. E. Walenkamp$^2$, Tessa Brabander$^4$, Wouter T. Zandee$^5$ and Walter Noordzij$^1$

Abstract

Background: In treatment of neuroendocrine neoplasms (NENs), confirmation of somatostatin receptor expression with $^{68}\text{Ga}$-DOTA somatostatin analogues is mandatory to determine eligibility for peptide receptor radionuclide therapy (PRRT). $[^{18}\text{F}]$DOPA can detect additional lesions compared to $[^{68}\text{Ga}]$DOTA-TOC. The aim of this study was to explore differences in tumour detection of both tracers and their relevance for selecting patients for PRRT. We retrospectively studied eight patients with NENs who underwent both $[^{68}\text{Ga}]$DOTA-TOC and carbidopa-enhanced $[^{18}\text{F}]$DOPA PET/CT, before first-time PRRT with $[^{177}\text{Lu}]$DOTA-TATE. Tracer order was influenced due to stock availability or to detect suspected metastases with a second tracer. On CT, disease control was defined as a lesion showing complete response, partial response, or stable disease, according to RECIST 1.1. criteria.

Results: Seven patients with in total 89 lesions completed four infusions of 7.4 GBq $[^{177}\text{Lu}]$DOTA-TATE, one patient received only two cycles. Before treatment, $[^{18}\text{F}]$DOPA PET/CT detected significantly more lesions than $[^{68}\text{Ga}]$DOTA-TOC PET/CT (79 vs. 62, $p<.001$). After treatment, no difference in number of lesions with disease control was found for $[^{18}\text{F}]$DOPA-only (5/27) and $[^{68}\text{Ga}]$DOTA-TOC-only lesions (4/10, $p=.25$). $[^{18}\text{F}]$DOPA detected more liver metastases (24/27) compared to $[^{68}\text{Ga}]$DOTA-TOC (7/10, $p=.006$). Six patients showed inpatient heterogeneity in treatment response between $[^{18}\text{F}]$DOPA-only and $[^{68}\text{Ga}]$DOTA-TOC-only lesions.

Conclusions: Response to PRRT with $[^{177}\text{Lu}]$DOTA-TATE was comparable for both $[^{68}\text{Ga}]$DOTA-TOC- and $[^{18}\text{F}]$DOPA-only NEN lesions. $[^{18}\text{F}]$DOPA may be capable of predicting response to PRRT while finding more lesions compared to $[^{68}\text{Ga}]$DOTA-TOC, although these additional lesions are often small of size and undetected by diagnostic CT.

Keywords: Neuroendocrine tumour, $[^{18}\text{F}]$DOPA, $[^{68}\text{Ga}]$DOTA-TOC, $[^{177}\text{Lu}]$DOTA-TATE, Peptide receptor radionuclide therapy, PRRT
Background

Neuroendocrine neoplasms (NENs) are a group of heterogeneous tumours with both neural and endocrine histological features. Neuroendocrine cells are typically regulated by numerous hormones, acting through specific receptors on the membrane surface. An overexpression of these receptors in most gastrointestinal NENs poses the basis for current functional PET/CT imaging and peptide receptor radionuclide therapy (PRRT) (Bodei et al. 2009).

PRRT using the somatostatin agonist tyrosine3-octreotate (DOTA-TATE) is an accepted treatment option for metastatic and non-resectable somatostatin receptor-positive NENs. Confirmation of receptor affinity, with 68Ga-labelled somatostatin analogues (SSAs) diagnostic imaging, is mandatory before determining a patient's eligibility for PRRT (Kwekkeboom et al. 2010). Three 68Ga-labelled SSA tracers are commonly used: DOTA-TATE, -TOC, and -NOC. The widespread introduction of PRRT for NEN was stimulated by the completion of the phase III NETTER-1 study (Strosberg et al. 2017). PRRT with 177Lu-labelled SSAs demonstrated treatment efficacy, with disease control rates ranging between 80 and 90% (Bodei et al. 2016; Kim et al. 2015; Brabander et al. 2017).

In clinical practice, more intense tumour 68Ga-labelled SSA uptake compared to normal liver parenchyma determines a patient's suitability for PRRT. However, somatostatin receptor (SSTR) distribution and density are sometimes limited (Wild et al. 2013; Sundin et al. 2007). For well-differentiated NEN tumours, another widely studied tracer is 6-1-[18F]fluoro-dihydroxyphenylalanine ([18F]DOPA). [18F]DOPA provides information about the dopamine pathway of tumour cells, which is often increased in NENs. The main clinical use for NEN imaging with [18F]DOPA is for midgut and hindgut NEN, certain paragangliomas, and NEN with low or variable SSTR expression (Bozkurt et al. 2017). [18F]DOPA offers increased image quality compared to [68Ga]DOTA-TOC, excelling in locating small intestinal tumours (Ambrosini et al. 2015). Although studies detailing the complex relation between glucose metabolism and SSTR expression exist (Oh et al. 2011), no studies have explored potential relationships between the dopamine pathway and SSTR presence.

As [18F]DOPA and [68Ga]DOTA-TOC utilize different aspects of tumour biology (Ambrosini et al. 2015), [18F]DOPA may identify lesions in tumours with weak or absent expression of SSTR. It is yet unclear if [18F]DOPA can be a substitute of [68Ga]DOTA-TOC in selecting PRRT candidates. We hypothesize that [18F]DOPA is equally capable in predicting response to PRRT, compared to [68Ga]DOTA-TOC. Therefore, in this study, we studied the lesion-based relationship between pre-treatment visualization on [18F]DOPA and [68Ga]DOTA-TOC PET/CT, and response to PRRT treatment.

Methods

Patients and study design

Eight patients who underwent both [68Ga]DOTA-TOC and [18F]DOPA PET/CT scanning before treatment with [177Lu]DOTA-TATE between May 2015 and February 2019 were retrospectively included in this case series. Pre- and post-treatment PET and CT scans were performed in the University Medical Center Groningen, while
PRRT was performed in the Erasmus Medical Center. All included patients had histologically proven NEN before their first-time treatment with PRRT. Median follow-up was 41 months (interquartile range [IQR]: 24–54) after first cycle of PRRT. Tumour grade (according to the 2010 World Health Organization classification) and therapy changes during follow-up were retrieved from the electronic patient chart (Kim et al. 2017).

Before PRRT, patients were confirmed, by [68Ga]DOTA-TOC PET/CT, to have sufficient SSTR presence in target lesions. Lesions were found to be sufficiently SSTR-active if [68Ga]DOTA-TOC uptake was higher than the liver. Additionally, due to suspicion of non-[68Ga]DOTA-TOC avid lesions or for logistical reasons, patients also received [18F]DOPA PET/CT. Suspicion might be due to finding hypodense [68Ga]DOTA-TOC non-avid lesion on diagnostic CT or due to mismatch of [68Ga]DOTA-TOC lesion appearance and clinical presentation. No [18F]FDG PET scans were performed, as there was no suspicion for G3 NET or NEC in the included patients.

[68Ga]DOTA-TOC and [18F]DOPA PET/CT
[68Ga]DOTA-TOC was produced using a Scintomics module and an Eckert and Ziegler [68Ge]/[68Ga] generator (Schultz et al. 2013). [18F]DOPA synthesis was performed as previously reported (Luurtsema et al. 2017). Imaging for both tracers was realized by a Siemens Biograph mCT (40 or 64 slices, 4 detector rings, Siemens Healthcare, Knoxville, TN, USA). Attenuation and scatter correction of the PET emission data was achieved by a low-dose CT scan with 120 kV and 35 mAs. Image reconstructions were obtained using three-dimensional ordinary Poisson ordered-subset expectation maximization with application of Time-of-Flight, three iterations, 21 subsets, and a Gaussian filter of 5 mm. The resulting image size was 400 x 400 with a voxel size of 2 x 204 x 204 mm. Contrast-enhanced CT scans of the chest and abdomen at baseline and response evaluation were obtained by using iodine-containing intravenous iomeprol (Iomeron) 350 mg/mL.

Patients were hydrated with 1 L of water before acquisition of both scans. Sixty minutes before the injection of [18F]DOPA, patients were pre-treated with carbidopa (2 mg/kg body weight, max. 150 mg). Patients received an intravenously injected dose of 200 megabecquerel (MBq) [18F]DOPA, or 120 MBq [68Ga]DOTA-TOC. Images were acquired after 60 ± 5 min, scanning from mid-thigh to head. [18F]DOPA PET/CT was acquired in 1.5 min per bed position in patients less than 60 kg body weight, 2 min per bed position in patients weighing 60–90 kg body weight and 3 min per bed position in patients over 90 kg body weight. [68Ga]DOTA-TOC PET/CT was acquired from proximal femur to head, with 3 min per bed position, irrespective of body weight.

177Lutetium treatment
A maximum of four cycles of 7.4 GBq of [177Lu]DOTA-TATE was intravenously infused over a timeframe of 30 min. Patients received infusions every 6 to 12 weeks (goal cumulative activity: 29.6 GBq). Preparation and administration protocol was described earlier (Zandee et al. 2019).
Image data analysis and statistics

Scans were analysed with Syngo.via (version VB30, Siemens Healthcare, Germany). Contrast-enhanced CT performed before and after PRRT was used to determine treatment effects and aided in verification of lesion malignancy together with radiological or histopathological reports. On PET/CT, a lesion was positive if a clear demarcated lesion could not be attributed to physiological uptake patterns. Results of both PET tracers were used to make lesion comparisons. On CT, longest axis diameters of all lesions were determined on the transverse plane. All individual lesions found by any PET tracer were cross-verified by their respective presentation on the CT scans, if any. Resulting CT-positive tumours were then individually labelled by their respective RECIST 1.1 categories: complete response (CR), partial response (PR), stable disease (SD), and progressive disease (PD). An additional category named ‘undetermined’ was created for positive PET/CT lesions with no substrate presence on CT. RECIST evaluation was not possible for these undetermined lesions. Disease control was present if a lesion was determined to be CR, PR, or SD.

Matching lesions were lesions that were seen by both tracers. A patient contained a mismatch pattern by having at least one lesion not detected by both tracers, while other lesions were concordant. Heterogeneity in treatment response occurred if a single patient had DOTA-TOC-only or matched lesions with at least one lesion with disease control (CR/PR/SD) and one without (PD).

Statistical analysis was performed using SPSS 23.0 software (SPSS Inc., Chicago, IL). Non-normally distributed outcomes were reported by medians and interquartile ranges. Chi-squared test was performed on all comparisons between $^{18}$FDOPA- and $^{68}$Ga DOTA-TOC-only lesions and Fisher’s exact test on RECIST score and tracer uptake subgroup (DOTA-TOC-only, DOPA-only, matched lesions). P values lower than 0.05 were considered to be significant.

Results

Patients

Eight patients (5 male, 3 female) with median age of 69 (IQR: 65–71) years old were included (Table 1). Seven patients had well-differentiated NENs (two G1, five G2), but for one patient, no tumour grading could be found. Primary tumour location was small intestine in five patients, colon in two, and lung in one. Before PRRT, ileo-caecal resection was performed in three patients, jejunal resection in one, and hemicolectomy in one. One patient had received everolimus and one patient interferon-gamma immunotherapy and telotristat for carcinoid syndrome. During PRRT, patients continued treatment with SSAs. All adverse events were self-limiting: two patients had minor gastrointestinal issues, two mild thrombocytopenia, two mild anaemia, and one mild neutropenia. Seven patients completed four infusions of 7.4 GBq $^{177}$LuDOTA-TATE, and one patient could not continue treatment because of progressive disease after two cycles.

Tumours

In total, more lesions were visualized with $^{18}$FDOPA PET/CT compared to $^{68}$Ga DOTA-TOC PET/CT (79 vs. 62, $p=0.00$, Table 2). Combining the results of both PET
### Table 1  Patient characteristics

| No | Age (years) | Sex | Primary tumour | Tumour grade (Ki-67) | Prior therapies | Current therapies | Diagnosis to start PRRT (months) | Time between [18F]DOPA and [68Ga] DOTA-TOC (months) | Time between PRRT-end and death (months) | PRRT cycles | Cumulative activity administered by PRRT (GBq) | Time between last PET/CT and start PRRT (months) | Pre-CT to PRRTa (months) | PRRT to Post-CTb (months) |
|----|-------------|-----|----------------|---------------------|------------------|------------------|----------------------------|---------------------------------|-----------------------------------|------------|-------------------------------|-----------------------------|------------------|-----------------------------|
| 1  | 55          | F   | SI             | G2 (2.8%)           | Everolimus, Surgery, interferon alpha, telotristat | Lanreotide, Lanreotide, Octreotide SA | 11                      | 5                               | –                                 | 4          | 30.1                           | 5                           | 0                | 2                           |
| 2  | 70          | M   | Colon          | G2 (3.5%)           | Everolimus, Surgery, interferon alpha, telotristat | Lanreotide, Lanreotide, Octreotide SA | 37                      | 13                              | –                                 | 4          | 29.9                           | 9                           | 2                | 2                           |
| 3  | 58          | F   | SI             | G2 (1.0%)           | Surgery           | Octreotide SA    | 39                      | 1                               | 5                                 | 2          | 14.9                           | 5                           | 2                | 2                           |
| 4  | 74          | M   | SI             | G1 (< 2%)           | Surgery           | Sandostatine SA  | 97                      | 1                               | –                                 | 4          | 30.1                           | 5                           | 5                | 11                          |
| 5  | 80          | M   | SI             | G2 (< 2%)           | Surgery           | Sandostatine SA  | 181                     | 1                               | –                                 | 4          | 29.6                           | 2                           | 3                | 2                           |
| 6  | 67          | M   | SI             | G2 (< 2%)           | Surgery           | Lanreotide, Octreotide SA | 107                   | 1                               | –                                 | 4          | 28.7                           | 3                           | 4                | 6                           |
| 7  | 69          | F   | Colon          | G1 (< 2%)           | Surgery, SSA      | Sandostatine, Octreotide SA | 38                      | 1                               | –                                 | 4          | 29.1                           | 2                           | 3                | 4                           |
| 8  | 70          | M   | Lung           | N/F (< 2%)          | Surgery           | Octreotide SA    | 36                      | 5                               | 27                                | 4          | 29.7                           | 3                           | 3                | 2                           |

*F, female; M, male; SI, small intestine; N/F, not found

a Days between last performed CT before PRRT and first PRRT-cycle, b days between last PRRT-cycle and first CT performed after PRRT
Table 2  Response per patient, as detected on [18F]DOPA and [68Ga]DOTA-TOC PET/CT

| No | TTP\(^a\) (months) | TTD\(^b\) (months) | RECIST (1-year) | Total lesions (n = 89) | Total matched lesions (n = 52) | Total DOPA lesions (n = 79) | Total DOPA-only lesions (n = 27) | DOPA-only tumour size (mm, mean) | Total DOTA lesions (n = 62) | DOTA-TOC-only lesions (n = 10) | DOTA-only tumour size (mm, mean) |
|----|-------------------|-------------------|----------------|------------------------|-------------------------------|----------------------------|--------------------------------|--------------------------------|--------------------------------|-------------------------------|-------------------------------|
| 1  | –                 | –                 | PR             | 10                     | 8                             | 10                         | 2                              | 42                              | 8                              | 0                             | 40                            |
| 2  | 18                | –                 | PR             | 7                      | 3                             | 14                         | 11                             | 19                              | 3                              | 0                             | 14                            |
| 3  | 0                 | 5                 | PD             | 8                      | 7                             | 8                          | 1                              | 27                              | 7                              | 0                             | 25                            |
| 4  | –                 | –                 | SD             | 10                     | 4                             | 4                          | 0                              | 18                              | 10                             | 6                             | 31                            |
| 5  | –                 | –                 | SD             | 18                     | 6                             | 17                         | 11                             | 25                              | 7                              | 1                             | 28                            |
| 6  | 15                | –                 | SD             | 14                     | 7                             | 7                          | 0                              | 16                              | 7                              | 0                             | 16                            |
| 7  | 14                | –                 | SD             | 7                      | 6                             | 7                          | 1                              | 23                              | 6                              | 0                             | 24                            |
| 8  | 7                 | 27                | PD             | 15                     | 11                            | 12                         | 1                              | 14                              | 14                             | 3                             | 41                            |

\(^a\) Time to progression; \(^b\) time to death (counting from date of last cycle of PRRT)
tracers counted 89 total and 52 matching lesions. Twenty-seven lesions were only found on [18F]DOPA PET/CT and 10 lesions were only found on [68Ga]DOTA-TOC PET/CT (Table 3). [18F]DOPA-only detected more liver metastases (24/27, 2 PR, 1 SD, 4 PD, 17 UD) compared to [68Ga]DOTA-TOC-only (7/10, 2 PR, 1 SD, 3 PD, 1 UD, \( p = 0.006 \)). Three mediastinal lesions were DOTA-TOC-only as well (1 PR, 2 UD).

Forty-five lesions (out of 89) were detected on pre- and post-PRRT CT, of which nine DOPA-only (3 PR, 2 SD, 4 PD), seven DOTA-TOC-only (3 PR, 1 SD, 3 PD), and 38 matching lesions (24 PR, 7 SD, 7 PD). Any difference found between lesion tracer uptake subgroup category and RECIST score was non-significant (\( p = 0.316 \)). Number of lesions showing disease control was not significantly different between DOPA-only (5/27) and DOTA-TOC-only lesions (4/10, \( p = 0.25 \)) and between all lesions found by both (\( p = 0.505 \)). Matching lesions were mostly in the liver (22/52, 10 PR, 4 SD, 3 PD, 5 PR, 5 UD). The remaining 30 matching lesions consisted of eight bone, eight mesenteric, six cardiac, four lymph, two pancreas, and two lung lesions. Seven out of eight patients showed mismatch results between tracer uptake on a lesion-based analysis. Mismatch results were located in the liver (32/37), mesenteric (2/37), and myocardial, mediastinal, paratracheal, and substernal (all had one).

In six patients, heterogeneity in treatment response was observed. Patient 1 showed treatment effect in several matching liver tumours, while a matched thoracic spinal lesion showed progression. The same event occurred in DOTA-TOC-only tumours: patient 4 had one liver lesion showing PR, while several other liver lesions being PD. DOPA-only lesions showed this effect as well: in patient 2, one liver lesion showed treatment response, while another showed progression (Fig. 1).

| Table 3 | Response per lesion location as detected on [18F]DOPA and [68 Ga]DOTA-TOC PET/CT a |
|---------|----------------------------------|
|         | Total number of lesions | Partial response | Stable disease | Progressive disease | Undetermined |
| DOPA tracer only | | | | | |
| Total | 27 | 3 | 2 | 4 | 18* |
| Liver | 24* | 2 | 1 | 1 | 17 |
| Mesentery | 2 | 1 | 1 | – | – |
| Cardiac | 1 | – | – | – | 1 |
| DOTA tracer only | | | | | |
| Total | 10 | 3 | 1 | 3 | 3* |
| Liver | 7* | 2 | 1 | 3 | 1 |
| Mediastinum | 3 | 1 | – | – | 2 |
| DOPA + DOTA tracer | | | | | |
| Total | 52 | 24 | 7 | 7 | 14 |
| Liver | 22 | 10 | 4 | 3 | 5 |
| Bone | 8 | – | 2 | 2 | 4 |
| Mesentery | 8 | 6 | 1 | 1 | – |
| Cardiac | 4 | – | – | 1 | 3 |
| Lymph nodes | 6 | 2 | 0 | 3 | 1 |
| Pancreas | 2 | 2 | – | – | – |
| Lung | 2 | 1 | – | – | 1 |

a No tumours with complete response were found

* Significant difference found between tracers (\( p < .05 \))
Follow-up

The one-year radiological response of the lesions (RECIST 1.1) was PR in two patients, SD in four, and PD in two. One patient had progressive disease after seven months, two patients after 15 months, and one patient after 18 months of follow-up. Two patients died during follow-up. One patient dropped out after the second cycle of PRRT with ongoing progressive disease and died five months afterwards. Another patient died after 27 months follow-up. Both deaths were due to end-stage metastatic liver disease.

Discussion

Our study showed that $^{18}$F]DOPA found a higher number of lesions compared to $^{68}$Ga DOTA-TOC. Generally, response to PRRT with $^{177}$LuDOTA-TATE was comparably predicted for both $^{68}$GaDOTA-TOC- and $^{18}$F]DOPA-only NEN lesions. While potentially incidental, we do note that of the 27 lesions visible with $^{18}$F]DOPA, three showed PR and four PD, which could suggest that non-$^{68}$GaDOTA-TOC avid lesions can respond to PRRT with $^{177}$Lu]DOTA-TATE. Both matching and mismatch lesions were predominantly found in the liver. In six patients, heterogeneity in treatment response was noted in both DOPA-only as DOTA-only lesions. In this small cohort, treatment with PRRT was generally effective at one-year follow-up, as six out of eight patients had disease control and two had progressive disease.

SSTR subtype targeting differences between diagnostic DOTA-TOC and therapeutic DOTA-TATE could explain conflicting results in found and responding lesions. Five SSTR subtypes have been identified, expressed in differing frequencies in NENs. As the majority of NENs express SSTR2 and 5, the use of PET/CT with $^{68}$Ga-labelled SSAs to determine eligibility has been the logical choice since the deployment of PRRT (Wild et al. 2013; Kwekkeboom and Krenning 2016). Several SSA PET tracers have consequently developed, all with different SSTR subtype targeting profiles. $^{68}$Ga
DOTA-TATE shows high affinity for SSTR2, [\(^{68}\text{Ga}\)]DOTA-TOC with SSTR2 and 5 (Bozkurt et al. 2017). Potentially, even better lesion detection rates could be achieved using [\(^{68}\text{Ga}\)]DOTA-NOC, displaying the highest affinity with SSTR2 and 5 (Wild et al. 2013). Additionally, SSTR antagonists are promising for imaging and treatment, due to more stable binding and expressing practically all SSTR subtypes, but currently lack large clinical trials (Bozkurt et al. 2017; Ginj et al. 2006; Minczeles et al. 2021).

SSTR heterogeneity of [\(^{68}\text{Ga}\)]DOTA-TOC within-tumour uptake is associated with worse response to PRRT (Graf et al. 2020), it is yet unknown if within-patient tracer uptake heterogeneity carries any prognostic value of response to PRRT. Our patients demonstrated one-sided heterogeneity of tracer uptake: only two out eight patients had both DOPA-only and DOTA-TOC-only lesions. This is further expanded by the finding that both DOPA-only and DOTA-TOC-only lesions showed heterogeneity in treatment response for six out of eight patients. Our study found four out of ten DOTA-TOC-only lesions showing treatment effect compared to four out of nine DOPA-only lesions. This challenges the notion that \(^{68}\text{Ga}\)-labelled SSAs positive and [\(^{18}\text{F}\)]DOPA negative lesions were more likely to respond to PRRT (Ambrosini et al. 2008). Our results show that DOTA-avid lesions can be dissimilarly affected by PRRT, and that DOPA-only lesions show treatment effect.

[\(^{18}\text{F}\)]DOPA is often used in low-SSTR NENs, although availability in clinical centres is usually less than DOTA. Discrepancies in tumour detection between [\(^{18}\text{F}\)]DOPA and [\(^{68}\text{Ga}\)]DOTA-TOC exist, as both tracers utilize different receptor pathways (Ambrosini et al. 2015). [\(^{18}\text{F}\)]DOPA identified many liver metastases that were not detected by [\(^{68}\text{Ga}\)]DOTA-TOC. Most of these [\(^{18}\text{F}\)]DOPA-only tumours were not seen on pre- and post-PRRT CT scans due to their small size (17/27). Although outside the scope of our study, we hypothesize that therapy response for undetermined [\(^{18}\text{F}\)]DOPA-only lesions could be established by dynamic contrast-enhanced MRI or PET/MRI. These small and often diffuse DOPA-only lesions in the liver could be a sign of new, and potentially poorly differentiated, metastasis of NEN. This is in accordance with findings that [\(^{18}\text{F}\)]DOPA PET/CT has been shown to more accurately evaluate small lesions with low-SSTR expression, such as poorly differentiated tumours (Ambrosini et al. 2008). Our finding that more lesions were found by [\(^{18}\text{F}\)]DOPA compared to [\(^{68}\text{Ga}\)]DOTA-TOC PET/CT are in contrast with previous comparative studies, which we commented on in our previous study (Veenstra et al. 2021). We cannot make a recommendations on dual-tracer imaging with [\(^{18}\text{F}\)]DOPA and [\(^{68}\text{Ga}\)]DOTA on patients before PRRT, based on small study population. In the case of non-DOTA-avid lesions, [\(^{18}\text{F}\)]DOPA might be considered as additional tracer, especially in G1 and G2 NEN. For selected cases, PRRT in G3 NEN is a developing and promising field of study and here dual-tracer imaging with [\(^{18}\text{F}\)]FDG would be appropriate instead of [\(^{18}\text{F}\)]DOPA.

Our study was limited by its retrospective scope and dropout of one patient, only finishing two cycles. Determining any effects of PRRT in this patient was exceedingly difficult, due to severe ascites present in post-PRRT CT scans. Several outliers in scan characteristics were apparent. One patient had large time frame between PET/CT scans (384 days, other patients 180) and PET/CT to PRRT (270 days, other patients < 170). Another patient reported a 330-day delay between PRRT and post-CT (other patients 180). Five patients had a follow-up CT at 2 months after completion of all PRRT cycles,
although uncommon, tumour pseudo progression due to radiation-induced oedema can occur which could have influenced the results of this study.

$[^{68}\text{Ga}]{\text{DOTA-TOC}}$ or $[^{68}\text{Ga}]{\text{DOTA-TATE PET/CT}}$ are the current diagnostic modalities to select patients for PRRT. In our case series, $[^{18}\text{F}]{\text{DOPA PET/CT}}$ showed more tumours compared to $[^{68}\text{Ga}]{\text{DOTA-TOC PET/CT}}$. Response to PRRT was comparable for both DOTA- and DOPA-only lesions, with $[^{18}\text{F}]{\text{DOPA}}$ finding more liver metastases. $[^{18}\text{F}]{\text{DOPA}}$ may be capable of predicting response to PRRT and can detect tumour receptor heterogeneity. Further prospective studies with controlled scan intervals and randomized tracer allocation are needed to improve clinical knowledge of $[^{18}\text{F}]{\text{DOPA}}$ in selecting and follow-up of PRRT in patients with NENs.

**Abbreviations**

PRRT: Peptide receptor radionuclide therapy; DOTA-TATE: DOTA-(Tyrosine)-octreotate; $[^{18}\text{F}]{\text{DOPA}}$: 6-L-$[^{18}\text{F}]$fluoro-dihydroxyphenylalanine; RECIST: Response evaluation criteria; SSAs: Somatostatin analogues; SSTR: Somatostatin receptor; CR: Complete response; PR: Partial response; SD: Stable disease; PD: Progressive disease.

**Acknowledgements**

Not applicable.

**Authors’ contributions**

All authors contributed to the study conception and design. Material preparation, data collection and analysis were performed by EBV and WN. The first draft of the manuscript was written by EBV and all authors commented on previous versions of the manuscript. All authors read and approved the final manuscript.

**Funding**

This study did not receive any funding.

**Availability of data and materials**

The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request.

**Declarations**

**Ethics approval and consent to participate**

According to the Dutch Medical Research Involving Human Subject Act, the local medical ethical committee exempted approval without additional procedures in view of the retrospective nature of the study and all the procedures being performed were part of the routine care.

**Consent for publication**

No additional informed consent was required.

**Competing interests**

The authors declare that they have no competing interests.

**Author details**

1 Medical Imaging Center, Department of Nuclear Medicine and Molecular Imaging, University of Groningen, University Medical Center Groningen, P.O. Box 30.001, 9700 RB Groningen, The Netherlands. 2 Department of Medical Oncology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands. 3 Department of Internal Medicine, Section of Endocrinology, Erasmus University Medical Center, Rotterdam, The Netherlands. 4 Department of Nuclear Medicine and Molecular Imaging, Erasmus University Medical Center, Rotterdam, The Netherlands. 5 Department of Internal Medicine, Section of Endocrinology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.

Received: 2 January 2022   Accepted: 23 March 2022

Published online: 15 June 2022

**References**

Ambrosini V, Moiigi JJ, Nanni C, Castellucci P, Fanti S (2015) Current status of PET imaging of neuroendocrine tumours ($[^{18}\text{F}]{\text{FDOPA}}, [^{68}\text{Ga}]\text{DOTA-NOC}, [^{11}C]/[^{18}F]HTP$). Q J Nucl Med Mol Imaging 59:58–69

Ambrosini V, Tomassetti P, Castellucci P, Campana D, Montini G, Rubello D et al (2008) Comparison between $^{68}\text{Ga-DOTA-NOC}$ and $^{18}\text{F-DOPA PET}$ for the detection of gastro-entero-pancreatic and lung neuro-endocrine tumours. Eur J Nucl Med Mol Imaging 35:1431–1438
Bodei L, Ferone D, Grana CM, Cremonesi M, Signore A, Dierckx RA et al (2009) Peptide receptor therapies in neuroendocrine tumors. J Endocrinol Invest. 32:360–9
Bodei L, Kwekkeboom DJ, Kidd M, Modlin IM, Krenning EP (2016) Radiolabeled somatostatin analogue therapy of gastroenteropancreatic. Cancer Semin Nucl Med 46:225–238
Bozkurt MF, Virgolini I, Balogova S, Beheshti M, Rubello D, Decristoforo C et al (2017) Guideline for PET/CT imaging of neuroendocrine neoplasms with 68Ga-DOTA-conjugated somatostatin receptor targeting peptides and 18F–DOPA. Eur J Nucl Med Mol Imaging 44:1588–1601
Brabander T, Van Der Zwan WA, Teunissen JIM, Kam BLR, Feelders RA, De Herder WW et al (2017) Long-term efficacy, survival, and safety of [177Lu-DOTA,Tyr3]octreotate in patients with gastroenteropancreatic and bronchial neuroendocrine tumors. Clin Cancer Res 23:4617–24
Ginj M, Zhang H, Waser B, Cescato R, Wild D, Wang X et al (2006) Radiolabeled somatostatin receptor antagonists are preferable to agonists for in vivo peptide receptor targeting of tumors. Proc Natl Acad Sci USA 103:16436–16441
Graf J, Pape UF, Jann H, Denecke T, Arsenic R, Brenner W et al (2020) Prognostic significance of somatostatin receptor heterogeneity in progressive neuroendocrine Tumor treated with Lu-177 DOTATOC or Lu-177 DOTATATE. Eur J Nucl Med Mol Imaging 47:881–894
Kim JY, Hong SM, Ro JY (2017) Recent updates on grading and classification of neuroendocrine tumors. Ann Diagn Pathol. 29:1–6
Kim S-JJ, Pak K, Koo PJ, Kwak JJ, Chang S (2015) The efficacy of [177Lu]-labelled peptide receptor radionuclide therapy in patients with neuroendocrine tumours: a meta-analysis. Eur J Nucl Med Mol Imaging 42:1964–70
Kwekkeboom DJ, Kam BL, Van Essen M, Teunissen JIM, Van Eijck CHJ, Valkema R et al (2010) Somatostatin receptor-based imaging and therapy of gastroenteropancreatic neuroendocrine tumors. Endocr Relat Cancer 17:R53–R73
Kwekkeboom DJ, Krenning EP (2016) Peptide receptor radionuclide therapy in the treatment of neuroendocrine tumors. Hematol Oncol Clin North Am 30:179–191
Luurtsema G, Boersma HH, Schepers M, de Vries AMT, Maas B, Zijlma R et al (2017) Improved GMP-compliant multi-dose production and quality control of 6-[18F]fluoro-L-DOPA. EJNMMI Radiopharm Chem 1:7
Minceles NS, Hofland J, de Herder WW, Brabander T (2021) Strategies towards improving clinical outcomes of peptide receptor radionuclide therapy. Curr Oncol Rep 23:1–11
Oh S, Prasad V, Lee DS, Baum RP (2011) Effect of peptide receptor radionuclide therapy on somatostatin receptor status and glucose metabolism in neuroendocrine tumors: intra-individual comparison of Ga-68 DOTA-NOC PET/CT and F-18 FDG PET/CT. Int J Mol Imaging 2011:1–7
Schultz MK, Mueller D, Baum RP, Leonard Watkins G, Breeman WAP (2013) A new automated NaCl based robust method for routine production of gallium-68 labeled peptides. Appl Radiat Isot 76:46–54
Strosberg J, El-Haddad G, Wolin E, Hendifar A, Yao J, Chasen B et al (2017) Phase 3 trial of 177Lu-dotatate for midgut neuroendocrine tumors. N Engl J Med 376:125–135
Sundin A, Garske U, Orfors H (2007) Nuclear imaging of neuroendocrine tumours. Best Pract Res Clin Endocrinol Metab 21:69–85
Veenstra EB, de Groot DJA, Brouwers AH, Walenkamp AME, Noordzij W (2021) Comparison of 18F-DOPA versus 68Ga-DOTATOC as preferred PET imaging tracer in well-differentiated neuroendocrine neoplasms. Clin Nucl Med 46:195–200
Wild D, Bomanji JB, Benkert P, Maecke H, Eil PI, Reubi JC et al (2013) Comparison of 68Ga-DOTANOC and 68Ga-DOTATATE PET/CT within patients with gastroenteropancreatic neuroendocrine tumors. J Nucl Med 54:364–372
Zandeek W, Brabander T, Blazevic A, Kam BLR, Teunissen JIM, Feelders RA et al (2019) Symptomatic and radiological response to 177Lu-DOTATATE for the treatment of functioning pancreatic neuroendocrine tumors. J Clin Endocrinol Metab 104:1336–1344

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.